There was lively discussion on stages, squares and festival tents at the SuomiAreena event in Pori in July. Health, well-being and employment were examined from various perspectives.
Asthma is a chronic inflammatory disease of the lungs. This glossary explains asthma terms, such as bronchodilator, anti-inflammatory medicine, inhaler, corticosteroid and spirometry.
Prostate cancer is the most widespread form of cancer that affects men, and approximately 5,000 men are diagnosed with prostate cancer every year. This form of cancer usually develops slowly and does not necessarily produce any symptoms. Forms of treatment are surgery or radiation therapy.
Wearing-off is a term that refers to a fluctuation in the symptoms of a person suffering from Parkinson’s disease. The patient’s symptoms fluctuate depending on the effects of the medication and the symptoms of the disease.
Noise anxiety is a common phobia among dogs. Treatment should always be targeted as a dog's behavior may be caused by a variety of reasons.
Orion develops new pharmaceuticals in three therapy areas. Orion’s pharmaceutical R&D focuses on the central nervous system, cancer and critical care, and inhalable Easyhaler® pulmonary drugs. Orion also develops veterinary and generic drugs.
Here we provide for download scientific publications released at congresses in which Orion is participating or in other contexts.
The Orion R&D aims to be the best in the world. Reijo Salonen, Senior Vice President of R&D, tells why and how.
What does it take to develop a new medicine? To start with, you need a dedicated team of top scientists and other professionals. The journey might take up to fifteen years. Take a look!
Orion published Half-Yearly Report for January-June 2016 on Tuesday 19 July 2016. The report and related presentation material is available here.
|9/7/2016||Composition of the Nomination Committee of Orion Corporation|
|7/19/2016||Orion Group Half-Yearly Report January-June 2016|
|7/19/2016||Orion Corporation's publication schedules for financial reporting in 2017|
|7/14/2016||100,000 Orion Corporation A shares converted into B shares|
Orion is a globally operating Finnish developer of pharmaceuticals and diagnostic tests – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests.
The 2016 Annual General Meeting of Orion was held on Tuesday, 22 March 2016 in Messukeskus Helsinki, Exhibition and Convention Centre.
The latest Corporate Governance Statement of Orion Corporation is available at the archive of Corporate Governance Statements.
One key area of Orion's business is Critical Care. Our portfolio includes Simdax® for acute heart failure and Precedex® and Dexdor® for sedation. Read more about Orion's proprietary products and other human pharmaceuticals.
Orion is the largest employer in the Finnish pharmaceutical industry. It is considered to be a good and reliable employer, which is also indicated by its lower-than-average employee turnover.
How do I apply for a job at Orion? Can I attach my CV to the application form? How can I make sure my job application stands out from the rest? These following tips will help you complete your job application.
Are you a physician, vet, pharmacist or another healthcare professional? 'Health Professionals' site offers an easy access to our websites for professionals.